A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

NCT05865886 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Bronchiectasis

Interventions

DRUG: BI 1291583
DRUG: Placebo to BI 1291583

Sponsor

Boehringer Ingelheim